Cancer
As the number of patients being diagnosed and living with cancer continues to grow, pharmacists are playing an increasingly important role in supporting patients, working within multidisciplinary teams and improving outcomes.
However, as the number of new cancer medicines is increasing and considering the potential for adverse effects with traditional and new anticancer therapies, it is now more important than ever for pharmacists to have a solid understanding of the principles of cancer biology, its diagnosis and approaches to treatment and prevention.
Our collection of oncology content, brought to you in partnership with BeiGene, has been organised into eight categories that can be accessed via the icons above or directly from the sections below.
If you have further topics that you would like to see included in the oncology collection, please contact the research and learning team.
Featured content
Management of Waldenstrom’s macroglobulinaemia
Supported content
How can pharmacists best support patients with chronic lymphocytic leukaemia?
Supported content
BTK inhibitors: what pharmacists need to know
Supported content
BRUKINSA is now reimbursed across the UK for R/R MZL
Promotional contentScreening and prevention
Cervical cancer prevention: advice and services
Colorectal cancer screening and the role of community pharmacy
Identifying patients with suspected cancer: red flags and referral
Solid cancers
Testicular cancer: symptoms, diagnosis and management
Lung cancer: screening, diagnosis and management
Prostate cancer: recognition and diagnosis
Liver cancer: screening, diagnosis and management
Renal cancer: management
Supported content
Bladder cancer: management
Supported content
Melanoma: risk factors and advice on sunscreen use
Lung cancer: advances in management and therapy
Prostate cancer: treatment options
Prostate cancer: risk factors and diagnosis
Leukaemias
Chronic lymphocytic leukaemia: diagnosis and management
Supported contentHow can pharmacists best support patients with chronic lymphocytic leukaemia?
Supported contentBTK inhibitors: what pharmacists need to know
Supported contentLymphomas and myelomas
Management of Waldenstrom’s macroglobulinaemia
Supported contentBTK inhibitors: what pharmacists need to know
Supported contentBRUKINSA is now reimbursed across the UK for R/R MZL
Promotional content
Monoclonal antibodies for the treatment of multiple myeloma
Multiple myeloma: pharmacological management
Treatment of acute and chronic lymphoid leukaemia
Lymphomas: current and future treatment options
Immunotherapy
Medication restrictions for patients receiving CAR-T therapy
Implementing chimeric antigen receptor T-cell therapy in practice
‘Beyond our wildest dreams’ – CAR-T therapies in multiple myeloma
Immuno-oncology agents for cancer therapy
Immune checkpoint inhibitors in cancer: pharmacology and toxicities
Immune-related cancer toxicities: what pharmacists need to know
Supported contentSide effects and toxicities
Cancer-associated thrombosis
Immune checkpoint inhibitors in cancer: pharmacology and toxicities
Immune-related cancer toxicities: what pharmacists need to know
Supported content
Overview of cancer treatment-related cardiovascular toxicity
Pharmacokinetic considerations and challenges in oral anticancer drug therapy
Patient care
Routine delays: the cancer services struggling to treat patients on time
How to support cancer patients in community pharmacies
How to counsel cancer patients about their oral chemotherapy
Pharmacogenomics and future perspectives
The role of circulating tumour DNA in guiding cancer treatment and future applications
How close are we to developing an mRNA cancer vaccine?
Cancer pharmacogenomics testing: are we hitting the mark?
DPYD genetic testing and the future of pharmacogenomic testing in routine care
The precision medicine approach to cancer therapy: part 1 — solid tumours
The precision medicine approach to cancer therapy: part 2 — haematological malignancies
Engineering precision: developing the next generation of antibody drug conjugates
About BeiGene
Over the past 13 years, BeiGene has redesigned how medicines are discovered and developed, from research and clinical development through to manufacturing and commercial operations.
BeiGene’s patient-centric philosophy is core to providing wide and rapid access to affordable, life-changing medicines globally, regardless of socioeconomic status. Our strategy means taking innovative approaches to clinical trials, enabling pricing and reimbursement flexibility within each market.
The BeiGene approach to developing medicines is distinct in the pharmaceutical/biotech industry, ensuring that patients’ needs are prioritised at every step, bringing maximal positive impact.
You can find out more about BeiGene here: beigene.co.uk
BeiGene has provided financial support for the creation of this dedicated hub page. The Pharmaceutical Journal does not have editorial control of this advertiser owned content labelled as ‘Promotional content’. However, The Pharmaceutical Journal retains editorial responsibility for independently created content that is financially supported by our commercial partners.